TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today gastroenterology roundup published Nov. 5 highlights estimates that gallbladder and biliary diseases affected more than 264 million people worldwide in 2023 and contributed to over 146,000 deaths. It also points to research questions about low-dose amitriptyline response in IBS and a Polish study linking large rectal polyps with higher odds of invasive cancer and recurrence than colonic lesions. The supplied report does not provide study methods or detailed results for the IBS and polyp findings.
A Nov. 5 gastroenterology roundup reported that gallbladder and biliary diseases affected more than 264 million people worldwide in 2023 and contributed to over 146,000 deaths, while also highlighting research on irritable bowel syndrome (IBS) and large rectal polyps. The report summarizes findings from several journals; the figures and study descriptions are attributed to the cited research, not presented as new estimates produced by MedPage Today.
The global figures cover conditions including gallstones, gallbladder inflammation and bile duct inflammation, described in the report as cholelithiasis, cholecystitis and cholangitis. The roundup attributes the estimates to research published in The Lancet Gastroenterology & Hepatology. It gives the disease count and deaths for 2023, but the supplied account does not include methods, country-level breakdowns or comparisons with earlier years.
On IBS, the report points to a study in Clinical Gastroenterology and Hepatology asking whether particular gastrointestinal and psychological symptom profiles can predict response to low-dose amitriptyline. It frames this as a research question; the supplied summary does not state which profiles were predictive, how many people took part or the size of any treatment effect.
A retrospective cohort study from Poland, published in Gut, found that after endoscopic removal of large colorectal polyps, rectal lesions were associated with greater likelihood of invasive cancer and recurrence than lesions in the colon. The roundup does not give absolute risks or specify how the results might change clinical follow-up. It also mentions other findings, including a federal report on hepatitis C treatment among Medicaid beneficiaries, but offers no detailed results for most items.
The Stakes Behind Three Findings
The biliary disease estimate describes a large global health burden: more than 264 million people affected and over 146,000 deaths in one year. Those totals can help readers and health professionals understand the scale of these conditions, but without the underlying study details they cannot show which diseases, populations or regions account for most of the burden, or whether it has risen or fallen.
The IBS item concerns whether symptom patterns could help identify who is more likely to respond to a commonly studied low-dose medicine. The roundup does not establish that a profile-based approach works or that amitriptyline is appropriate for any particular person. The rectal-polyp finding may matter because it signals a difference in outcomes by lesion location in the studied patients. Since the report provides no absolute risk estimates, readers should not infer an individual prognosis from the association.
Products Worth Considering
Garmin Forerunner 70 GPS Running Smartwatch, 43 mm, Black
BowFlex Results Series SelectTech Adjustable Dumbbells (Pair)
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
As an affiliate, we earn on qualifying purchases.
Research Across Digestive Health
The source is a short MedPage Today gastroenterology and hepatology roundup by managing editor Ian Ingram, published Nov. 5, 2026. It groups research and professional updates from multiple publications rather than reporting one new clinical guideline or a single original study. The three topics in the headline sit alongside items on liver disease, inflammatory bowel disease and endoscopic care.
The report says global gallbladder and biliary disease estimates refer to 2023. Separately, it describes the IBS work as investigating possible predictors of response and the Polish polyp research as a retrospective cohort study. Those distinctions matter: an investigation of a predictor is not a treatment recommendation, and an observed association in a retrospective study does not by itself establish cause and effect.
“Can certain gastrointestinal and psychological symptom profiles in irritable bowel syndrome predict response to low-dose amitriptyline?”
— MedPage Today roundup, summarizing research in Clinical Gastroenterology and Hepatology
Study Details Still Missing
The supplied report does not identify the methods behind the 2023 global estimates, their uncertainty ranges, or how cases and deaths were defined. It also does not say how the totals compare with earlier years, so no trend can be drawn from the figures provided.
For the IBS study, the summary leaves out its sample size, symptom categories, results and treatment-effect measurements. For the rectal-polyp study, it gives no absolute rates, follow-up period, participant characteristics or adjustments for other risk factors. It is also unclear from this account whether either study’s findings have led to changes in clinical guidance. The results described here should not be treated as individual medical advice.
Full Studies Will Add Detail
The next step for readers seeking a fuller account is to consult the original studies cited in The Lancet Gastroenterology & Hepatology, Clinical Gastroenterology and Hepatology and Gut. Those papers can provide study design, populations, methods and numerical results that are absent from the roundup. The source does not announce a specific follow-up date, guideline decision or next research milestone.
Until those details are available in the supplied material, the confirmed takeaway is limited: the report summarizes a substantial 2023 global burden estimate and flags two separate areas of digestive research. Any implications for treatment choices or surveillance require the full evidence and, for personal care decisions, discussion with a qualified health professional.
Key Questions
How many people were affected by gallbladder and biliary diseases in 2023?
The roundup reports that more than 264 million people worldwide had these diseases in 2023. It attributes the figure to research in The Lancet Gastroenterology & Hepatology.
How many deaths were attributed to these diseases?
The reported estimate is over 146,000 deaths in 2023. The source summary does not provide country-level figures or comparisons with other years.
Does the report show that amitriptyline works for a particular IBS symptom profile?
No. It says a study examined whether gastrointestinal and psychological symptom profiles could predict response to low-dose amitriptyline, but does not provide the study’s results or effect sizes.
What did the study report about large rectal polyps?
A retrospective Polish cohort study linked rectal lesions with a higher likelihood of invasive cancer and recurrence than colonic lesions after endoscopic removal of large colorectal polyps. The roundup does not give absolute risk estimates or establish cause and effect.
Source: medpagetoday.com
